This study demonstrates that a sequential approach, starting with NET and using Ki67 levels and clinical response to guide the addition of CDK4/6i and chemotherapy, is both feasible and effective for ER/PGR>50 %, HER2-and TP53 wild-type breast cancers. Here, MKI67 is linked to breast carcinoma.